Cost-effectiveness of clozapine in patients with high and low levels of hospital use

Archives of General Psychiatry

Volumn 56, Issue 6, 1999, Pages 565-572

  Rosenheck, Robert ^a,b,f   Cramer, Joyce ^a   Allan, Edward ^c,d   Erdos, Joseph ^a   Frisman, Linda K ^e   Xu, Weichun ^c   Thomas, Jonathan ^c   Henderson, William ^c   Charney, Dennis ^a  

^a West Haven   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e Connecticut Dept Mental Hlth A ^*  (United States)

^f VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; HALOPERIDOL;

ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG USE; HUMAN; MAJOR CLINICAL STUDY; SCHIZOPHRENIA; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; COST-BENEFIT ANALYSIS; CROSS-OVER STUDIES; DRUG COSTS; FEMALE; HALOPERIDOL; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; RESEARCH DESIGN; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0032973979     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.56.6.565     Document Type: Article

References (35)

1. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
2. Hargreaves WA, Shumway M, Hu TW, Cuffel B. Cost-Outcome Methods for Mental Health. San Diego, Calif: Academic Press; 1997.
3. Weisbrod B, Test MA, Stein LI. Alternative to mental hospital treatment, II: economic cost benefit analysis. Arch Gen Psychiatry. 1980;37:400-405.
4. Rosenheck RA, Neale MS. Cost-effectiveness of intensive psychiatric community care for high users of inpatient services. Arch Gen Psychiatry. 1998;55:459-466.
5. Rosenheck RA, Cramer J, Xu W, Thomas J, Henderson W, Frisman LK, Fye C, Charney D, for the Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. A comparison of clozapine and haloperidol in the treatment of hospitalized patients with refractory schizophrenia. N Engl J Med. 1987;337:809-815.
6. Lave JR, Frank RG, Schulberg HC, Kamlet MS. Cost-effectiveness of treatments for depression in primary care practice. Arch Gen Psychiatry. 1998;55:645-651.
7. Essock SM, Hargreaves WA, Covell NH, Goethe J. Clozapine's effectivenenss for patients in state hospitals: results from a randomized trial. Psychopharmacol Bull. 1996;32:683-697.
8. Meltzer HY, Cola P, Way L. Cost-effectiveness of clozapine in neuroleptic resistant schizophrenia. Am J Psychiatry. 1993;150:1630-1638.
9. Revicki DA, Luce BR, Wechsler JM, Brown RE, Adler MA. Cost-effectiveness of clozapine for treatment resistant schizophrenic patients. Hosp Community Psychiatry. 1990;41:850-854.
10. Reid WH, Mason M. Psychiatric hospital utilization in patients treated with clozapine for up to 4.5 years in a state mental health care system. J Clin Psychiatry. 1998;59:189-194;
11. Rosenheck RA, Massari L, Frisman L. Who should receive high cost mental health treatment and for how long? issues in the rationing of mental health care. Schizophr Bull. 1993;19:843-852.
12. Rosenheck RA, Neale M, Leaf P, Milstein R, Frisman L. Multisite experimental cost study of intensive psychiatric community care. Schizophr Bull. 1995;21: 129-140.
13. Essock SM, Frisman LK, Kontos NJ. Cost-effectiveness of assertive community treatment teams. Am Orthopsychiatry. 1998;68(2):179-190.
14. Kane JM, Honigfeld G, Singer J, Meltzer HY, and the Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic: a double blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789-796.
15. Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A, Kronig M, Bookstein P, Kane JM. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry. 1994; 151:1744-1752.
16. Carpenter WT, Conley RR, Buchanan RW, Breier A, Tamminga C. Patient response and resource management: another view of clozapine treatment of schizophrenia. Am J Psychiatry. 1996;152:827-832.
17. Buchanan RW. Clozapine: efficacy and safety. Schizopnr Bull. 1995;21:579-591.
18. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition. Washington, DC: American Psychiatric Association; 1987.
19. Spitzer RS, Endicott JE. The Semi-structured Clinical Interview for Diagnosis. Washington, DC: American Psychiatric Press; 1990.
20. Guy W. Clinical Global Impression. In: Guy W, ed. ECDEU Assessment Manual for Psychopharamcology. Rockville, Md: National Institute of Mental Health; 1976. Publication DHEW ADM 76-338.
21. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962; 10:799-812.
22. Rosenheck R, Tekall J, Peters J, Cramer J, Fontana A, Xu W, Thomas J, Henderson W, Charney D. Does participation in psychosocial treatment augment the benefit of clozapine? Arch Gen Psychiatry. 1998;55:618-625.
23. Rosenheck RA, Neale M, Frisman L. Issues in stimating the cost of innovative mental health programs. Psychiatr Q. 1995;66:9-31.
24. Rosenheck RA, Frisman L, Neale M. Estimating the capital component of mental health care costs in the public sector. Admin Policy Mental Health. 1994;21:493-509.
25. Office of the Inspector General. Comparison of Costs and Outcomes of Matched Pairs of VAMCs and Their University Affiliates. Washington, DC: Office of the Inspector General; 1992.
26. Kay SR, Fishbein G, Opler DR. The positive and negative syndrome scale (PANSS) for schizophrenia. Schiz Bull. 1987;13:261-276.
27. Heinrichs DW, Hanlon ET, Carpenter WT. The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schiz Bull. 1984;10:388-398.
28. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand. 1970;212(suppl):11-19.
29. Rosenheck RA, Cramer J, Xu W, Grabowski J, Douyon R, Thomas J, Henderson W. Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Health Serv Res. 1998;33: 1235-1259.
30. Bryk AA, Raudenbush SW. Hierarchical Linear Models. Newbury Park, Calif: Sage Publications: 1992.
31. Weinstein MC. From cost-effectiveness ratios to resource allocation: where to draw the line. In: Sloan FA, ed. Valuing Health Care. New York, NY: Cambridge University Press; 1996.
32. Johanneson M. Theory and Methods of Economic Evaluation of Health Care. Dordrecht, the Netherlands: Kluwer Academic Publishers; 1996.
33. Luchins DJ, Hanrahan P, Schinderman M, Lagios L, Fichtner. Initiating clozapine treatment in the outpatient clinic: service utilization and cost trends. Psychiatr Serv. 1998;9:1034-1038.
34. Leslie DL, Rosenheck RA. Shifting from inpatient to outpatient care? mental health utilization and costs in a privately insured population. Am Psychiatry. In press.
35. Zhang M, Owen RR, Pope SK, Smith GR. Cost-effectiveness of clozpaine monitoring after the first 6 months. Arch General Psychiatry. 53:954-958.